nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—L-DOPA—Melphalan—ovarian cancer	0.625	1	CrCrCtD
Epinephrine—Skin necrosis—Melphalan—ovarian cancer	0.00502	0.0288	CcSEcCtD
Epinephrine—Extravasation—Carboplatin—ovarian cancer	0.00448	0.0257	CcSEcCtD
Epinephrine—Skin necrosis—Vinorelbine—ovarian cancer	0.00439	0.0252	CcSEcCtD
Epinephrine—Rales—Melphalan—ovarian cancer	0.00428	0.0245	CcSEcCtD
Epinephrine—ADRBK1—embryo—ovarian cancer	0.00363	0.0682	CbGeAlD
Epinephrine—TNF—vagina—ovarian cancer	0.00347	0.0651	CbGeAlD
Epinephrine—Tachyarrhythmia—Epirubicin—ovarian cancer	0.00323	0.0185	CcSEcCtD
Epinephrine—Peripheral coldness—Vinorelbine—ovarian cancer	0.00322	0.0185	CcSEcCtD
Epinephrine—Local reaction—Melphalan—ovarian cancer	0.00317	0.0182	CcSEcCtD
Epinephrine—Tachyarrhythmia—Doxorubicin—ovarian cancer	0.00299	0.0171	CcSEcCtD
Epinephrine—Skin necrosis—Paclitaxel—ovarian cancer	0.00295	0.0169	CcSEcCtD
Epinephrine—Local reaction—Vinorelbine—ovarian cancer	0.00277	0.0159	CcSEcCtD
Epinephrine—ADRBK1—gonad—ovarian cancer	0.00247	0.0463	CbGeAlD
Epinephrine—Lactic acidosis—Epirubicin—ovarian cancer	0.00241	0.0139	CcSEcCtD
Epinephrine—ADRB3—female reproductive system—ovarian cancer	0.00225	0.0423	CbGeAlD
Epinephrine—TNF—lymph node—ovarian cancer	0.00224	0.0421	CbGeAlD
Epinephrine—Lactic acidosis—Doxorubicin—ovarian cancer	0.00223	0.0128	CcSEcCtD
Epinephrine—ADRBK1—female reproductive system—ovarian cancer	0.0022	0.0413	CbGeAlD
Epinephrine—Tingling sensation—Melphalan—ovarian cancer	0.00218	0.0125	CcSEcCtD
Epinephrine—Peripheral coldness—Paclitaxel—ovarian cancer	0.00216	0.0124	CcSEcCtD
Epinephrine—ADRBK1—bone marrow—ovarian cancer	0.00208	0.039	CbGeAlD
Epinephrine—Extravasation—Topotecan—ovarian cancer	0.00205	0.0118	CcSEcCtD
Epinephrine—ADRB3—female gonad—ovarian cancer	0.00205	0.0385	CbGeAlD
Epinephrine—Isoprenaline—MAPK1—ovarian cancer	0.00204	1	CrCbGaD
Epinephrine—Extravasation—Melphalan—ovarian cancer	0.00201	0.0115	CcSEcCtD
Epinephrine—ADRBK1—female gonad—ovarian cancer	0.002	0.0376	CbGeAlD
Epinephrine—ADRBK1—vagina—ovarian cancer	0.00199	0.0374	CbGeAlD
Epinephrine—Necrosis—Vinorelbine—ovarian cancer	0.00195	0.0112	CcSEcCtD
Epinephrine—Myocardial ischaemia—Vinorelbine—ovarian cancer	0.00191	0.0109	CcSEcCtD
Epinephrine—ADRBK1—testis—ovarian cancer	0.00178	0.0334	CbGeAlD
Epinephrine—Extravasation—Vinorelbine—ovarian cancer	0.00176	0.0101	CcSEcCtD
Epinephrine—ADRA1D—epithelium—ovarian cancer	0.00171	0.032	CbGeAlD
Epinephrine—Skin necrosis—Epirubicin—ovarian cancer	0.00169	0.00968	CcSEcCtD
Epinephrine—Skin exfoliation—Melphalan—ovarian cancer	0.00167	0.00961	CcSEcCtD
Epinephrine—Hemiplegia—Epirubicin—ovarian cancer	0.00165	0.00947	CcSEcCtD
Epinephrine—Supraventricular tachycardia—Paclitaxel—ovarian cancer	0.00157	0.00903	CcSEcCtD
Epinephrine—Skin necrosis—Doxorubicin—ovarian cancer	0.00156	0.00896	CcSEcCtD
Epinephrine—Hemiplegia—Doxorubicin—ovarian cancer	0.00153	0.00876	CcSEcCtD
Epinephrine—Skin exfoliation—Vinorelbine—ovarian cancer	0.00146	0.0084	CcSEcCtD
Epinephrine—Pulmonary oedema—Vinorelbine—ovarian cancer	0.00136	0.00783	CcSEcCtD
Epinephrine—Dizziness—Altretamine—ovarian cancer	0.00134	0.00767	CcSEcCtD
Epinephrine—Supraventricular tachycardia—Docetaxel—ovarian cancer	0.00133	0.00765	CcSEcCtD
Epinephrine—Necrosis—Paclitaxel—ovarian cancer	0.00131	0.00754	CcSEcCtD
Epinephrine—ADRBK1—lymph node—ovarian cancer	0.00129	0.0242	CbGeAlD
Epinephrine—Vomiting—Altretamine—ovarian cancer	0.00128	0.00737	CcSEcCtD
Epinephrine—Myocardial ischaemia—Paclitaxel—ovarian cancer	0.00128	0.00736	CcSEcCtD
Epinephrine—Tingling sensation—Paclitaxel—ovarian cancer	0.00128	0.00736	CcSEcCtD
Epinephrine—ADRA1D—female reproductive system—ovarian cancer	0.00127	0.0238	CbGeAlD
Epinephrine—Nausea—Altretamine—ovarian cancer	0.0012	0.00689	CcSEcCtD
Epinephrine—ADRA2C—myometrium—ovarian cancer	0.00119	0.0223	CbGeAlD
Epinephrine—Extravasation—Paclitaxel—ovarian cancer	0.00118	0.00678	CcSEcCtD
Epinephrine—Contusion—Paclitaxel—ovarian cancer	0.00118	0.00678	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Paclitaxel—ovarian cancer	0.00114	0.00655	CcSEcCtD
Epinephrine—SLC22A5—myometrium—ovarian cancer	0.00114	0.0214	CbGeAlD
Epinephrine—Cerebrovascular accident—Vinorelbine—ovarian cancer	0.00114	0.00652	CcSEcCtD
Epinephrine—Necrosis—Docetaxel—ovarian cancer	0.00111	0.00639	CcSEcCtD
Epinephrine—Drug interaction—Paclitaxel—ovarian cancer	0.00111	0.00638	CcSEcCtD
Epinephrine—Myocardial ischaemia—Docetaxel—ovarian cancer	0.00109	0.00624	CcSEcCtD
Epinephrine—Local reaction—Epirubicin—ovarian cancer	0.00106	0.00611	CcSEcCtD
Epinephrine—Blood pressure increased—Paclitaxel—ovarian cancer	0.00103	0.00592	CcSEcCtD
Epinephrine—Hallucination—Chlorambucil—ovarian cancer	0.00101	0.00577	CcSEcCtD
Epinephrine—Extravasation—Docetaxel—ovarian cancer	0.001	0.00575	CcSEcCtD
Epinephrine—Local reaction—Doxorubicin—ovarian cancer	0.000985	0.00565	CcSEcCtD
Epinephrine—Skin exfoliation—Paclitaxel—ovarian cancer	0.000984	0.00565	CcSEcCtD
Epinephrine—ADRA1A—epithelium—ovarian cancer	0.00098	0.0184	CbGeAlD
Epinephrine—Sweating—Topotecan—ovarian cancer	0.000961	0.00552	CcSEcCtD
Epinephrine—ADRA2A—myometrium—ovarian cancer	0.00095	0.0178	CbGeAlD
Epinephrine—Drug interaction—Docetaxel—ovarian cancer	0.000942	0.00541	CcSEcCtD
Epinephrine—ADRA2C—uterine cervix—ovarian cancer	0.000926	0.0174	CbGeAlD
Epinephrine—Lightheadedness—Paclitaxel—ovarian cancer	0.000922	0.00529	CcSEcCtD
Epinephrine—ADRB1—female reproductive system—ovarian cancer	0.000921	0.0173	CbGeAlD
Epinephrine—Haemoglobin—Topotecan—ovarian cancer	0.000904	0.00519	CcSEcCtD
Epinephrine—Haemorrhage—Topotecan—ovarian cancer	0.0009	0.00516	CcSEcCtD
Epinephrine—Hypoaesthesia—Topotecan—ovarian cancer	0.000895	0.00514	CcSEcCtD
Epinephrine—SLC22A5—uterine cervix—ovarian cancer	0.000887	0.0167	CbGeAlD
Epinephrine—Haemoglobin—Melphalan—ovarian cancer	0.000885	0.00508	CcSEcCtD
Epinephrine—ADRA2C—decidua—ovarian cancer	0.000883	0.0166	CbGeAlD
Epinephrine—Haemorrhage—Melphalan—ovarian cancer	0.000881	0.00506	CcSEcCtD
Epinephrine—Blood pressure increased—Docetaxel—ovarian cancer	0.000874	0.00502	CcSEcCtD
Epinephrine—SLC22A1—vagina—ovarian cancer	0.000865	0.0162	CbGeAlD
Epinephrine—Acute coronary syndrome—Vinorelbine—ovarian cancer	0.000845	0.00485	CcSEcCtD
Epinephrine—Myocardial infarction—Vinorelbine—ovarian cancer	0.00084	0.00482	CcSEcCtD
Epinephrine—ADRA2C—endometrium—ovarian cancer	0.000838	0.0157	CbGeAlD
Epinephrine—Skin exfoliation—Docetaxel—ovarian cancer	0.000834	0.00479	CcSEcCtD
Epinephrine—Flushing—Melphalan—ovarian cancer	0.000817	0.00469	CcSEcCtD
Epinephrine—Agitation—Chlorambucil—ovarian cancer	0.000808	0.00464	CcSEcCtD
Epinephrine—SLC22A5—endometrium—ovarian cancer	0.000803	0.0151	CbGeAlD
Epinephrine—Ventricular arrhythmia—Epirubicin—ovarian cancer	0.000796	0.00457	CcSEcCtD
Epinephrine—Arrhythmia—Melphalan—ovarian cancer	0.000787	0.00452	CcSEcCtD
Epinephrine—Renal impairment—Paclitaxel—ovarian cancer	0.000786	0.00451	CcSEcCtD
Epinephrine—Lightheadedness—Docetaxel—ovarian cancer	0.000782	0.00449	CcSEcCtD
Epinephrine—Pulmonary oedema—Docetaxel—ovarian cancer	0.000778	0.00446	CcSEcCtD
Epinephrine—ADRA2C—uterus—ovarian cancer	0.000772	0.0145	CbGeAlD
Epinephrine—Hypoglycaemia—Paclitaxel—ovarian cancer	0.000767	0.0044	CcSEcCtD
Epinephrine—Hypoaesthesia—Vinorelbine—ovarian cancer	0.000766	0.0044	CcSEcCtD
Epinephrine—Cerebrovascular accident—Paclitaxel—ovarian cancer	0.000763	0.00438	CcSEcCtD
Epinephrine—Necrosis—Epirubicin—ovarian cancer	0.000751	0.00431	CcSEcCtD
Epinephrine—ADRA2A—uterine cervix—ovarian cancer	0.000739	0.0139	CbGeAlD
Epinephrine—Ventricular arrhythmia—Doxorubicin—ovarian cancer	0.000737	0.00423	CcSEcCtD
Epinephrine—Flushing—Vinorelbine—ovarian cancer	0.000714	0.0041	CcSEcCtD
Epinephrine—ADRA2A—decidua—ovarian cancer	0.000704	0.0132	CbGeAlD
Epinephrine—Necrosis—Doxorubicin—ovarian cancer	0.000695	0.00399	CcSEcCtD
Epinephrine—Arrhythmia—Vinorelbine—ovarian cancer	0.000687	0.00395	CcSEcCtD
Epinephrine—Hypokalaemia—Paclitaxel—ovarian cancer	0.000681	0.00391	CcSEcCtD
Epinephrine—Extravasation—Epirubicin—ovarian cancer	0.000675	0.00388	CcSEcCtD
Epinephrine—Erythema—Vinorelbine—ovarian cancer	0.00067	0.00385	CcSEcCtD
Epinephrine—ADRA2A—endometrium—ovarian cancer	0.000669	0.0125	CbGeAlD
Epinephrine—Chest pain—Topotecan—ovarian cancer	0.000667	0.00383	CcSEcCtD
Epinephrine—Renal impairment—Docetaxel—ovarian cancer	0.000666	0.00383	CcSEcCtD
Epinephrine—SLC22A5—female reproductive system—ovarian cancer	0.000665	0.0125	CbGeAlD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000662	0.0038	CcSEcCtD
Epinephrine—Chest pain—Melphalan—ovarian cancer	0.000653	0.00375	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Epirubicin—ovarian cancer	0.000652	0.00375	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000648	0.00372	CcSEcCtD
Epinephrine—ADRA2C—female gonad—ovarian cancer	0.000632	0.0119	CbGeAlD
Epinephrine—Sweating increased—Paclitaxel—ovarian cancer	0.00063	0.00362	CcSEcCtD
Epinephrine—ADRA2C—vagina—ovarian cancer	0.000628	0.0118	CbGeAlD
Epinephrine—Nervous system disorder—Topotecan—ovarian cancer	0.000627	0.0036	CcSEcCtD
Epinephrine—Extravasation—Doxorubicin—ovarian cancer	0.000625	0.00359	CcSEcCtD
Epinephrine—Skin disorder—Topotecan—ovarian cancer	0.000621	0.00356	CcSEcCtD
Epinephrine—ADRA2A—gonad—ovarian cancer	0.00062	0.0116	CbGeAlD
Epinephrine—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00062	0.00356	CcSEcCtD
Epinephrine—Hyperhidrosis—Topotecan—ovarian cancer	0.000618	0.00355	CcSEcCtD
Epinephrine—ADRA2A—uterus—ovarian cancer	0.000616	0.0116	CbGeAlD
Epinephrine—Tachycardia—Melphalan—ovarian cancer	0.000611	0.00351	CcSEcCtD
Epinephrine—Skin disorder—Melphalan—ovarian cancer	0.000608	0.00349	CcSEcCtD
Epinephrine—SLC22A5—female gonad—ovarian cancer	0.000605	0.0114	CbGeAlD
Epinephrine—Ventricular extrasystoles—Doxorubicin—ovarian cancer	0.000604	0.00347	CcSEcCtD
Epinephrine—SLC22A5—vagina—ovarian cancer	0.000601	0.0113	CbGeAlD
Epinephrine—Palpitations—Vinorelbine—ovarian cancer	0.000592	0.0034	CcSEcCtD
Epinephrine—Hyperglycaemia—Paclitaxel—ovarian cancer	0.000583	0.00335	CcSEcCtD
Epinephrine—Hypertension—Vinorelbine—ovarian cancer	0.000578	0.00332	CcSEcCtD
Epinephrine—Paraesthesia—Topotecan—ovarian cancer	0.000574	0.00329	CcSEcCtD
Epinephrine—CYP2C9—female reproductive system—ovarian cancer	0.000572	0.0107	CbGeAlD
Epinephrine—Chest pain—Vinorelbine—ovarian cancer	0.00057	0.00327	CcSEcCtD
Epinephrine—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.000568	0.00326	CcSEcCtD
Epinephrine—Renal failure—Paclitaxel—ovarian cancer	0.000567	0.00325	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000566	0.00325	CcSEcCtD
Epinephrine—Myocardial infarction—Paclitaxel—ovarian cancer	0.000565	0.00324	CcSEcCtD
Epinephrine—Skin exfoliation—Epirubicin—ovarian cancer	0.000563	0.00323	CcSEcCtD
Epinephrine—Paraesthesia—Melphalan—ovarian cancer	0.000562	0.00323	CcSEcCtD
Epinephrine—ADRA2C—testis—ovarian cancer	0.00056	0.0105	CbGeAlD
Epinephrine—ADRA2A—female reproductive system—ovarian cancer	0.000554	0.0104	CbGeAlD
Epinephrine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000552	0.00317	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00054	0.0031	CcSEcCtD
Epinephrine—SLC22A5—testis—ovarian cancer	0.000537	0.0101	CbGeAlD
Epinephrine—Nervous system disorder—Vinorelbine—ovarian cancer	0.000536	0.00308	CcSEcCtD
Epinephrine—Tachycardia—Vinorelbine—ovarian cancer	0.000534	0.00306	CcSEcCtD
Epinephrine—Skin disorder—Vinorelbine—ovarian cancer	0.000531	0.00305	CcSEcCtD
Epinephrine—Pulmonary oedema—Epirubicin—ovarian cancer	0.000524	0.00301	CcSEcCtD
Epinephrine—Skin exfoliation—Doxorubicin—ovarian cancer	0.000521	0.00299	CcSEcCtD
Epinephrine—Haemoglobin—Paclitaxel—ovarian cancer	0.00052	0.00299	CcSEcCtD
Epinephrine—Haemorrhage—Paclitaxel—ovarian cancer	0.000518	0.00297	CcSEcCtD
Epinephrine—Hypoaesthesia—Paclitaxel—ovarian cancer	0.000515	0.00296	CcSEcCtD
Epinephrine—ADRA2A—female gonad—ovarian cancer	0.000504	0.00946	CbGeAlD
Epinephrine—ADRA2A—vagina—ovarian cancer	0.000501	0.0094	CbGeAlD
Epinephrine—Paraesthesia—Vinorelbine—ovarian cancer	0.000491	0.00282	CcSEcCtD
Epinephrine—Pulmonary oedema—Doxorubicin—ovarian cancer	0.000485	0.00279	CcSEcCtD
Epinephrine—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000482	0.00277	CcSEcCtD
Epinephrine—Renal failure—Docetaxel—ovarian cancer	0.00048	0.00276	CcSEcCtD
Epinephrine—Flushing—Paclitaxel—ovarian cancer	0.00048	0.00276	CcSEcCtD
Epinephrine—Myocardial infarction—Docetaxel—ovarian cancer	0.000479	0.00275	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000472	0.00271	CcSEcCtD
Epinephrine—Arrhythmia—Paclitaxel—ovarian cancer	0.000462	0.00265	CcSEcCtD
Epinephrine—Vomiting—Chlorambucil—ovarian cancer	0.000456	0.00262	CcSEcCtD
Epinephrine—Mental disorder—Paclitaxel—ovarian cancer	0.000453	0.0026	CcSEcCtD
Epinephrine—Erythema—Paclitaxel—ovarian cancer	0.000451	0.00259	CcSEcCtD
Epinephrine—Renal impairment—Epirubicin—ovarian cancer	0.000449	0.00258	CcSEcCtD
Epinephrine—ADRA2A—testis—ovarian cancer	0.000447	0.00839	CbGeAlD
Epinephrine—Tension—Paclitaxel—ovarian cancer	0.000442	0.00254	CcSEcCtD
Epinephrine—Haemoglobin—Docetaxel—ovarian cancer	0.000441	0.00253	CcSEcCtD
Epinephrine—Haemorrhage—Docetaxel—ovarian cancer	0.000439	0.00252	CcSEcCtD
Epinephrine—Hypoglycaemia—Epirubicin—ovarian cancer	0.000438	0.00252	CcSEcCtD
Epinephrine—Nervousness—Paclitaxel—ovarian cancer	0.000438	0.00251	CcSEcCtD
Epinephrine—Hypoaesthesia—Docetaxel—ovarian cancer	0.000437	0.00251	CcSEcCtD
Epinephrine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.000436	0.00251	CcSEcCtD
Epinephrine—CYP3A4—female reproductive system—ovarian cancer	0.000436	0.00818	CbGeAlD
Epinephrine—Nausea—Chlorambucil—ovarian cancer	0.000426	0.00245	CcSEcCtD
Epinephrine—Dizziness—Topotecan—ovarian cancer	0.000423	0.00243	CcSEcCtD
Epinephrine—Renal impairment—Doxorubicin—ovarian cancer	0.000416	0.00239	CcSEcCtD
Epinephrine—Agitation—Paclitaxel—ovarian cancer	0.000414	0.00238	CcSEcCtD
Epinephrine—Flushing—Docetaxel—ovarian cancer	0.000407	0.00234	CcSEcCtD
Epinephrine—Vomiting—Topotecan—ovarian cancer	0.000406	0.00233	CcSEcCtD
Epinephrine—ADRA2C—lymph node—ovarian cancer	0.000406	0.00762	CbGeAlD
Epinephrine—Hypoglycaemia—Doxorubicin—ovarian cancer	0.000406	0.00233	CcSEcCtD
Epinephrine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000404	0.00232	CcSEcCtD
Epinephrine—Palpitations—Paclitaxel—ovarian cancer	0.000398	0.00229	CcSEcCtD
Epinephrine—Vomiting—Melphalan—ovarian cancer	0.000398	0.00228	CcSEcCtD
Epinephrine—Arrhythmia—Docetaxel—ovarian cancer	0.000392	0.00225	CcSEcCtD
Epinephrine—Hypokalaemia—Epirubicin—ovarian cancer	0.000389	0.00223	CcSEcCtD
Epinephrine—Hypertension—Paclitaxel—ovarian cancer	0.000389	0.00223	CcSEcCtD
Epinephrine—SLC22A5—lymph node—ovarian cancer	0.000389	0.0073	CbGeAlD
Epinephrine—Mental disorder—Docetaxel—ovarian cancer	0.000384	0.00221	CcSEcCtD
Epinephrine—Chest pain—Paclitaxel—ovarian cancer	0.000384	0.0022	CcSEcCtD
Epinephrine—Erythema—Docetaxel—ovarian cancer	0.000382	0.00219	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000381	0.00219	CcSEcCtD
Epinephrine—Nausea—Topotecan—ovarian cancer	0.00038	0.00218	CcSEcCtD
Epinephrine—Nausea—Melphalan—ovarian cancer	0.000372	0.00213	CcSEcCtD
Epinephrine—Dizziness—Vinorelbine—ovarian cancer	0.000362	0.00208	CcSEcCtD
Epinephrine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000361	0.00207	CcSEcCtD
Epinephrine—Hypokalaemia—Doxorubicin—ovarian cancer	0.00036	0.00207	CcSEcCtD
Epinephrine—Tachycardia—Paclitaxel—ovarian cancer	0.000359	0.00206	CcSEcCtD
Epinephrine—Skin disorder—Paclitaxel—ovarian cancer	0.000357	0.00205	CcSEcCtD
Epinephrine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000355	0.00204	CcSEcCtD
Epinephrine—Vomiting—Vinorelbine—ovarian cancer	0.000348	0.002	CcSEcCtD
Epinephrine—Palpitations—Docetaxel—ovarian cancer	0.000337	0.00194	CcSEcCtD
Epinephrine—Hyperglycaemia—Epirubicin—ovarian cancer	0.000333	0.00191	CcSEcCtD
Epinephrine—Insomnia—Paclitaxel—ovarian cancer	0.000333	0.00191	CcSEcCtD
Epinephrine—Paraesthesia—Paclitaxel—ovarian cancer	0.00033	0.0019	CcSEcCtD
Epinephrine—Hypertension—Docetaxel—ovarian cancer	0.00033	0.00189	CcSEcCtD
Epinephrine—Drowsiness—Epirubicin—ovarian cancer	0.00033	0.00189	CcSEcCtD
Epinephrine—Somnolence—Paclitaxel—ovarian cancer	0.000327	0.00188	CcSEcCtD
Epinephrine—Chest pain—Docetaxel—ovarian cancer	0.000325	0.00187	CcSEcCtD
Epinephrine—Nausea—Vinorelbine—ovarian cancer	0.000325	0.00186	CcSEcCtD
Epinephrine—Renal failure—Epirubicin—ovarian cancer	0.000324	0.00186	CcSEcCtD
Epinephrine—ADRA2A—lymph node—ovarian cancer	0.000324	0.00608	CbGeAlD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000323	0.00185	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000317	0.00182	CcSEcCtD
Epinephrine—Sweating—Epirubicin—ovarian cancer	0.000316	0.00181	CcSEcCtD
Epinephrine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000309	0.00177	CcSEcCtD
Epinephrine—Nervous system disorder—Docetaxel—ovarian cancer	0.000306	0.00175	CcSEcCtD
Epinephrine—Drowsiness—Doxorubicin—ovarian cancer	0.000305	0.00175	CcSEcCtD
Epinephrine—Tachycardia—Docetaxel—ovarian cancer	0.000304	0.00175	CcSEcCtD
Epinephrine—Skin disorder—Docetaxel—ovarian cancer	0.000303	0.00174	CcSEcCtD
Epinephrine—Renal failure—Doxorubicin—ovarian cancer	0.0003	0.00172	CcSEcCtD
Epinephrine—Haemoglobin—Epirubicin—ovarian cancer	0.000297	0.00171	CcSEcCtD
Epinephrine—Haemorrhage—Epirubicin—ovarian cancer	0.000296	0.0017	CcSEcCtD
Epinephrine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000294	0.00169	CcSEcCtD
Epinephrine—Sweating—Doxorubicin—ovarian cancer	0.000292	0.00168	CcSEcCtD
Epinephrine—Insomnia—Docetaxel—ovarian cancer	0.000282	0.00162	CcSEcCtD
Epinephrine—Paraesthesia—Docetaxel—ovarian cancer	0.00028	0.00161	CcSEcCtD
Epinephrine—Somnolence—Docetaxel—ovarian cancer	0.000277	0.00159	CcSEcCtD
Epinephrine—Haemoglobin—Doxorubicin—ovarian cancer	0.000275	0.00158	CcSEcCtD
Epinephrine—Flushing—Epirubicin—ovarian cancer	0.000275	0.00158	CcSEcCtD
Epinephrine—Haemorrhage—Doxorubicin—ovarian cancer	0.000274	0.00157	CcSEcCtD
Epinephrine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000272	0.00156	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000269	0.00154	CcSEcCtD
Epinephrine—Arrhythmia—Epirubicin—ovarian cancer	0.000264	0.00152	CcSEcCtD
Epinephrine—Mental disorder—Epirubicin—ovarian cancer	0.000259	0.00149	CcSEcCtD
Epinephrine—Erythema—Epirubicin—ovarian cancer	0.000258	0.00148	CcSEcCtD
Epinephrine—Flushing—Doxorubicin—ovarian cancer	0.000254	0.00146	CcSEcCtD
Epinephrine—Tension—Epirubicin—ovarian cancer	0.000253	0.00145	CcSEcCtD
Epinephrine—Nervousness—Epirubicin—ovarian cancer	0.00025	0.00144	CcSEcCtD
Epinephrine—Arrhythmia—Doxorubicin—ovarian cancer	0.000245	0.0014	CcSEcCtD
Epinephrine—Dizziness—Paclitaxel—ovarian cancer	0.000243	0.0014	CcSEcCtD
Epinephrine—Mental disorder—Doxorubicin—ovarian cancer	0.00024	0.00138	CcSEcCtD
Epinephrine—Erythema—Doxorubicin—ovarian cancer	0.000238	0.00137	CcSEcCtD
Epinephrine—Agitation—Epirubicin—ovarian cancer	0.000237	0.00136	CcSEcCtD
Epinephrine—Tension—Doxorubicin—ovarian cancer	0.000234	0.00134	CcSEcCtD
Epinephrine—Vomiting—Paclitaxel—ovarian cancer	0.000234	0.00134	CcSEcCtD
Epinephrine—Nervousness—Doxorubicin—ovarian cancer	0.000231	0.00133	CcSEcCtD
Epinephrine—Palpitations—Epirubicin—ovarian cancer	0.000228	0.00131	CcSEcCtD
Epinephrine—Hypertension—Epirubicin—ovarian cancer	0.000222	0.00128	CcSEcCtD
Epinephrine—Chest pain—Epirubicin—ovarian cancer	0.000219	0.00126	CcSEcCtD
Epinephrine—Agitation—Doxorubicin—ovarian cancer	0.000219	0.00126	CcSEcCtD
Epinephrine—Nausea—Paclitaxel—ovarian cancer	0.000218	0.00125	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000218	0.00125	CcSEcCtD
Epinephrine—Palpitations—Doxorubicin—ovarian cancer	0.000211	0.00121	CcSEcCtD
Epinephrine—Nervous system disorder—Epirubicin—ovarian cancer	0.000206	0.00118	CcSEcCtD
Epinephrine—Dizziness—Docetaxel—ovarian cancer	0.000206	0.00118	CcSEcCtD
Epinephrine—Hypertension—Doxorubicin—ovarian cancer	0.000206	0.00118	CcSEcCtD
Epinephrine—Tachycardia—Epirubicin—ovarian cancer	0.000205	0.00118	CcSEcCtD
Epinephrine—Skin disorder—Epirubicin—ovarian cancer	0.000204	0.00117	CcSEcCtD
Epinephrine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000203	0.00117	CcSEcCtD
Epinephrine—Chest pain—Doxorubicin—ovarian cancer	0.000203	0.00116	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000202	0.00116	CcSEcCtD
Epinephrine—Vomiting—Docetaxel—ovarian cancer	0.000198	0.00114	CcSEcCtD
Epinephrine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000191	0.0011	CcSEcCtD
Epinephrine—Insomnia—Epirubicin—ovarian cancer	0.00019	0.00109	CcSEcCtD
Epinephrine—Tachycardia—Doxorubicin—ovarian cancer	0.00019	0.00109	CcSEcCtD
Epinephrine—Skin disorder—Doxorubicin—ovarian cancer	0.000189	0.00108	CcSEcCtD
Epinephrine—Paraesthesia—Epirubicin—ovarian cancer	0.000189	0.00108	CcSEcCtD
Epinephrine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000188	0.00108	CcSEcCtD
Epinephrine—Somnolence—Epirubicin—ovarian cancer	0.000187	0.00107	CcSEcCtD
Epinephrine—Nausea—Docetaxel—ovarian cancer	0.000185	0.00106	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000181	0.00104	CcSEcCtD
Epinephrine—Insomnia—Doxorubicin—ovarian cancer	0.000176	0.00101	CcSEcCtD
Epinephrine—Paraesthesia—Doxorubicin—ovarian cancer	0.000175	0.001	CcSEcCtD
Epinephrine—Somnolence—Doxorubicin—ovarian cancer	0.000173	0.000993	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000168	0.000964	CcSEcCtD
Epinephrine—Dizziness—Epirubicin—ovarian cancer	0.000139	0.000798	CcSEcCtD
Epinephrine—Vomiting—Epirubicin—ovarian cancer	0.000134	0.000767	CcSEcCtD
Epinephrine—Dizziness—Doxorubicin—ovarian cancer	0.000129	0.000738	CcSEcCtD
Epinephrine—Nausea—Epirubicin—ovarian cancer	0.000125	0.000717	CcSEcCtD
Epinephrine—Vomiting—Doxorubicin—ovarian cancer	0.000124	0.00071	CcSEcCtD
Epinephrine—Nausea—Doxorubicin—ovarian cancer	0.000116	0.000663	CcSEcCtD
Epinephrine—ADRA2C—Signaling Pathways—ERBB2—ovarian cancer	8.55e-06	5.86e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—HRAS—ovarian cancer	8.51e-06	5.84e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CDKN1B—ovarian cancer	8.48e-06	5.81e-05	CbGpPWpGaD
Epinephrine—ADRB1—GPCR downstream signaling—AKT1—ovarian cancer	8.46e-06	5.8e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3CD—ovarian cancer	8.46e-06	5.8e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PIK3CB—ovarian cancer	8.44e-06	5.78e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MTOR—ovarian cancer	8.44e-06	5.78e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—AKT1—ovarian cancer	8.43e-06	5.78e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—FASN—ovarian cancer	8.43e-06	5.78e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—ERBB2—ovarian cancer	8.41e-06	5.77e-05	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR downstream signaling—AKT1—ovarian cancer	8.38e-06	5.75e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CASP3—ovarian cancer	8.38e-06	5.75e-05	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—PIK3CA—ovarian cancer	8.38e-06	5.74e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—IL2—ovarian cancer	8.37e-06	5.74e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CDKN1B—ovarian cancer	8.37e-06	5.74e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PTEN—ovarian cancer	8.35e-06	5.73e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—IL6—ovarian cancer	8.33e-06	5.71e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CASP3—ovarian cancer	8.31e-06	5.69e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MTOR—ovarian cancer	8.3e-06	5.69e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PIK3CB—ovarian cancer	8.3e-06	5.69e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—IL2—ovarian cancer	8.29e-06	5.69e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—IL6—ovarian cancer	8.29e-06	5.68e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	8.29e-06	5.68e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	8.28e-06	5.68e-05	CbGpPWpGaD
Epinephrine—ADRB2—GPCR downstream signaling—AKT1—ovarian cancer	8.28e-06	5.67e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—IL6—ovarian cancer	8.25e-06	5.66e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CASP3—ovarian cancer	8.2e-06	5.62e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PIK3CB—ovarian cancer	8.19e-06	5.62e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—ABCB1—ovarian cancer	8.19e-06	5.61e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—IL2—ovarian cancer	8.19e-06	5.61e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CCND1—ovarian cancer	8.16e-06	5.59e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	8.15e-06	5.59e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—IL6—ovarian cancer	8.15e-06	5.58e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	8.15e-06	5.58e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CXCL8—ovarian cancer	8.11e-06	5.56e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CCND1—ovarian cancer	8.09e-06	5.54e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CTNNB1—ovarian cancer	8.08e-06	5.54e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—HRAS—ovarian cancer	8.05e-06	5.52e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—TYMS—ovarian cancer	8.04e-06	5.51e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CTNNB1—ovarian cancer	8.01e-06	5.49e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	8.01e-06	5.49e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CCND1—ovarian cancer	7.98e-06	5.47e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	7.98e-06	5.47e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	7.93e-06	5.43e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MMP9—ovarian cancer	7.92e-06	5.43e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CDKN1B—ovarian cancer	7.92e-06	5.43e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CTNNB1—ovarian cancer	7.9e-06	5.42e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PTEN—ovarian cancer	7.88e-06	5.4e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	7.86e-06	5.39e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MMP9—ovarian cancer	7.85e-06	5.38e-05	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR downstream signaling—AKT1—ovarian cancer	7.83e-06	5.37e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—VEGFA—ovarian cancer	7.81e-06	5.35e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PTEN—ovarian cancer	7.8e-06	5.35e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	7.79e-06	5.34e-05	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	7.79e-06	5.34e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CASP3—ovarian cancer	7.76e-06	5.32e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MMP9—ovarian cancer	7.75e-06	5.31e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL2—ovarian cancer	7.75e-06	5.31e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—STAT3—ovarian cancer	7.73e-06	5.3e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—NRAS—ovarian cancer	7.71e-06	5.29e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—IL6—ovarian cancer	7.71e-06	5.28e-05	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	7.71e-06	5.28e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PTEN—ovarian cancer	7.7e-06	5.28e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	7.7e-06	5.28e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—AKT1—ovarian cancer	7.68e-06	5.27e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	7.68e-06	5.26e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—AKT1—ovarian cancer	7.65e-06	5.24e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	7.64e-06	5.23e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL2—ovarian cancer	7.62e-06	5.23e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	7.61e-06	5.22e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	7.61e-06	5.22e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	7.59e-06	5.2e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CAV1—ovarian cancer	7.58e-06	5.2e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CCND1—ovarian cancer	7.55e-06	5.18e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—AKT1—ovarian cancer	7.52e-06	5.15e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CTNNB1—ovarian cancer	7.48e-06	5.13e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	7.47e-06	5.12e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	7.43e-06	5.1e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MAPK3—ovarian cancer	7.39e-06	5.06e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	7.37e-06	5.06e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	7.37e-06	5.06e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	7.36e-06	5.05e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	7.33e-06	5.03e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	7.29e-06	5e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.25e-06	4.97e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	7.22e-06	4.95e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MYC—ovarian cancer	7.18e-06	4.92e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	7.17e-06	4.92e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—VEGFA—ovarian cancer	7.11e-06	4.88e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	7.11e-06	4.87e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	7.09e-06	4.86e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PTEN—ovarian cancer	7.08e-06	4.85e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	7.07e-06	4.85e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	7.05e-06	4.83e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—STAT3—ovarian cancer	7.04e-06	4.83e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	7.04e-06	4.83e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	7.03e-06	4.82e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—NRAS—ovarian cancer	7.03e-06	4.82e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	7.03e-06	4.82e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	7e-06	4.8e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	6.98e-06	4.78e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	6.96e-06	4.77e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—VEGFA—ovarian cancer	6.96e-06	4.77e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	6.94e-06	4.76e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	6.92e-06	4.74e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	6.91e-06	4.74e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—STAT3—ovarian cancer	6.89e-06	4.72e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—NRAS—ovarian cancer	6.87e-06	4.71e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	6.85e-06	4.7e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	6.85e-06	4.7e-05	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	6.85e-06	4.69e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	6.81e-06	4.67e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	6.78e-06	4.65e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL2—ovarian cancer	6.77e-06	4.64e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	6.74e-06	4.62e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	6.73e-06	4.61e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	6.67e-06	4.57e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	6.64e-06	4.55e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	6.6e-06	4.53e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	6.58e-06	4.51e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	6.58e-06	4.51e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MAPK3—ovarian cancer	6.58e-06	4.51e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MYC—ovarian cancer	6.54e-06	4.49e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	6.54e-06	4.48e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	6.54e-06	4.48e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	6.52e-06	4.47e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	6.5e-06	4.46e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MYC—ovarian cancer	6.49e-06	4.45e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CAV1—ovarian cancer	6.48e-06	4.44e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	6.48e-06	4.44e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	6.43e-06	4.41e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	6.42e-06	4.4e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	6.41e-06	4.39e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	6.4e-06	4.39e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MYC—ovarian cancer	6.4e-06	4.39e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—EGFR—ovarian cancer	6.4e-06	4.39e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	6.4e-06	4.39e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	6.37e-06	4.37e-05	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	6.36e-06	4.36e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	6.34e-06	4.35e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	6.34e-06	4.35e-05	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PIK3CA—ovarian cancer	6.32e-06	4.33e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ABCB1—ovarian cancer	6.32e-06	4.33e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	6.3e-06	4.32e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	6.29e-06	4.31e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MAPK1—ovarian cancer	6.26e-06	4.29e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—EGFR—ovarian cancer	6.26e-06	4.29e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	6.26e-06	4.29e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	6.23e-06	4.27e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	6.22e-06	4.26e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—TYMS—ovarian cancer	6.21e-06	4.26e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.19e-06	4.24e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PIK3CA—ovarian cancer	6.15e-06	4.22e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	6.13e-06	4.21e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	6.13e-06	4.2e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	6.1e-06	4.18e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	6.07e-06	4.16e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	6.07e-06	4.16e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MYC—ovarian cancer	6.06e-06	4.15e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—KRAS—ovarian cancer	6.05e-06	4.15e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	5.99e-06	4.11e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	5.96e-06	4.09e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	5.96e-06	4.08e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	5.93e-06	4.06e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	5.93e-06	4.06e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	5.92e-06	4.06e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—KRAS—ovarian cancer	5.92e-06	4.06e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	5.9e-06	4.05e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TP53—ovarian cancer	5.9e-06	4.04e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PIK3CA—ovarian cancer	5.89e-06	4.04e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	5.83e-06	4e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	5.83e-06	4e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	5.78e-06	3.96e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	5.76e-06	3.95e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	5.7e-06	3.91e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	5.69e-06	3.9e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	5.64e-06	3.87e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	5.6e-06	3.84e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	5.56e-06	3.81e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	5.51e-06	3.78e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	5.51e-06	3.77e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	5.44e-06	3.73e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PIK3CA—ovarian cancer	5.43e-06	3.73e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—IL6—ovarian cancer	5.4e-06	3.7e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TP53—ovarian cancer	5.37e-06	3.68e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	5.35e-06	3.67e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TP53—ovarian cancer	5.33e-06	3.65e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	5.3e-06	3.63e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	5.3e-06	3.63e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	5.29e-06	3.63e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	5.28e-06	3.62e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TP53—ovarian cancer	5.26e-06	3.6e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	5.19e-06	3.56e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	5.18e-06	3.55e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	5.18e-06	3.55e-05	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—AKT1—ovarian cancer	5.17e-06	3.54e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	5.14e-06	3.53e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—HRAS—ovarian cancer	5.14e-06	3.52e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	5.09e-06	3.49e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	5.06e-06	3.47e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	5.06e-06	3.47e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—HRAS—ovarian cancer	5.03e-06	3.45e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—AKT1—ovarian cancer	5.02e-06	3.44e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CAV1—ovarian cancer	5e-06	3.43e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	5e-06	3.42e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	4.98e-06	3.41e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TP53—ovarian cancer	4.97e-06	3.41e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	4.92e-06	3.37e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—IL6—ovarian cancer	4.92e-06	3.37e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	4.9e-06	3.36e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	4.89e-06	3.35e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—IL6—ovarian cancer	4.87e-06	3.34e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—AKT1—ovarian cancer	4.81e-06	3.3e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	4.81e-06	3.3e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—IL6—ovarian cancer	4.81e-06	3.3e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	4.81e-06	3.3e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	4.76e-06	3.26e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	4.68e-06	3.21e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTEN—ovarian cancer	4.57e-06	3.14e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.56e-06	3.12e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL6—ovarian cancer	4.55e-06	3.12e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	4.55e-06	3.12e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—AKT1—ovarian cancer	4.54e-06	3.11e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	4.52e-06	3.1e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	4.5e-06	3.08e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	4.5e-06	3.08e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	4.48e-06	3.07e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—AKT1—ovarian cancer	4.44e-06	3.04e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	4.35e-06	2.98e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	4.2e-06	2.88e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	4.18e-06	2.86e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	4.16e-06	2.85e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	4.13e-06	2.83e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—AKT1—ovarian cancer	4.08e-06	2.8e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	4.04e-06	2.77e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	4.01e-06	2.75e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	3.98e-06	2.73e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTEN—ovarian cancer	3.91e-06	2.68e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	3.86e-06	2.65e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	3.7e-06	2.54e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	3.67e-06	2.52e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.49e-06	2.39e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	3.41e-06	2.34e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	3.23e-06	2.21e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTEN—ovarian cancer	3.02e-06	2.07e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.76e-06	1.89e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—AKT1—ovarian cancer	2.64e-06	1.81e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—AKT1—ovarian cancer	2.25e-06	1.54e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.13e-06	1.46e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—AKT1—ovarian cancer	1.74e-06	1.19e-05	CbGpPWpGaD
